MR angiography of aortoiliac occlusive disease : A phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325GOYEN, Mathias; EDELMAN, Mark; KENT YUCEL, E et al.Radiology. 2005, Vol 236, Num 3, pp 825-833, issn 0033-8419, 9 p.Article

What are the reasons for negative phase III trials of molecular-target-based drugs?SAIJO, Nagahiro.Cancer science. 2004, Vol 95, Num 10, pp 772-776, issn 1347-9032, 5 p.Article

Inference of Unexpected Genetic Relatedness among Individuals in HapMap Phase IIIPEMBERTON, Trevor J; CHAOLONG WANG; LI, Jun Z et al.American journal of human genetics. 2010, Vol 87, Num 4, pp 457-464, issn 0002-9297, 8 p.Article

The importance of reporting patient recruitment details in phase III trialsWRIGHT, James R; BOUMA, Sarah; DAYES, Ian et al.Journal of clinical oncology. 2006, Vol 24, Num 6, pp 843-847, issn 0732-183X, 5 p.Article

Phase III Clinical Trial Development: A Process of Chutes and LaddersDILTS, David M; CHENG, Steven K; CRITES, Joshua S et al.Clinical cancer research (Print). 2010, Vol 16, Num 22, pp 5381-5389, issn 1078-0432, 9 p.Article

Using a drug before the risks and benefits are known from a phase 3 clinical trial : Thoughts on compassionMILLER, Joan W.Archives of ophthalmology (1960). 2006, Vol 124, Num 7, pp 1029-1031, issn 0003-9950, 3 p.Article

Disclosure of competing financial interests and role of sponsors in phase III cancer trialsTUECH, Jean-Jacques; MOUTEL, Grégoire; PESSAUX, Patrick et al.European journal of cancer (1990). 2005, Vol 41, Num 15, pp 2237-2240, issn 0959-8049, 4 p.Article

Accrual Experience of National Cancer Institute Cooperative Group Phase III Trials Activated From 2000 to 2007KORN, Edward L; FREIDLIN, Boris; MOONEY, Margaret et al.Journal of clinical oncology. 2010, Vol 28, Num 35, pp 5197-5201, issn 0732-183X, 5 p.Article

The benefits of participation in clinical trialsVAN DONGEN, J. A; VAN DE VELDE, C. J. H.European journal of surgical oncology. 1996, Vol 22, Num 6, pp 561-562, issn 0748-7983Article

Phase III Clinical Trials That Integrate Treatment and Biomarker EvaluationFREIDLIN, Boris; ZHUOXIN SUN; GRAY, Robert et al.Journal of clinical oncology. 2013, Vol 31, Num 25, pp 3158-3161, issn 0732-183X, 4 p.Article

Time to mandate data release and independent audits for all clinical trialsHAINES, Ian E; GABOR MIKLOS, George L.Medical journal of Australia. 2011, Vol 195, Num 10, pp 575-577, issn 0025-729X, 3 p.Article

Responsiveness of NEI VFQ-25 to Changes in Visual Acuity in Neovascular AMD: Validation Studies from Two Phase 3 Clinical TrialsSUNER, Ivan J; KOKAME, Gregg T; YU, Elaine et al.Investigative ophthalmology & visual science. 2009, Vol 50, Num 8, pp 3629-3635, issn 0146-0404, 7 p.Article

Peut-on prédire la bonne posologie de la phase III ? = Ho<w to predict the therapeutic dose range to be tested in phase III clinical trials?DAHAN, R; JAILLON, P; LEHNER, J. P et al.Thérapie (Paris). 1993, Vol 48, Num 4, pp 297-301, issn 0040-5957Conference Paper

Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological responseVINGERHOETS, Johan; RIMSKY, Laurence; VAN EYGEN, Veerle et al.Antiviral therapy (London). 2013, Vol 18, Num 2, pp 253-256, issn 1359-6535, 4 p.Article

Design Issues in Randomized Phase II/III TrialsKORN, Edward L; FREIDLIN, Boris; ABRAMS, Jeffrey S et al.Journal of clinical oncology. 2012, Vol 30, Num 6, pp 667-671, issn 0732-183X, 5 p.Article

Efficacy and Safety of the Betamethasone Valerate 0.1% Plaster in Mild-to-Moderate Chronic Plaque Psoriasis: A Randomized, Parallel-Group, Active-Controlled, Phase III StudyNALDI, Luigi; YAWALKAR, Nikhil; KASZUBA, Andrzej et al.American journal of clinical dermatology. 2011, Vol 12, Num 3, pp 191-201, issn 1175-0561, 11 p.Article

Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III studyHEE CHUL EUN; OH SANG KWON; HWA YOUNG PARK et al.Journal of the American Academy of Dermatology. 2010, Vol 63, Num 2, pp 252-258, issn 0190-9622, 7 p.Article

Phase II/III randomized trial of TCH346 in patients with ALSMILLER, R; BRADLEY, W; STRONG, M et al.Neurology. 2007, Vol 69, Num 8, pp 776-784, issn 0028-3878, 9 p.Article

Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2MELBY, T; SISTA, P; DEMASI, R et al.AIDS research and human retroviruses. 2006, Vol 22, Num 5, pp 375-385, issn 0889-2229, 11 p.Article

Reducing the costs of phase III cardiovascular clinical trialsEISENSTEIN, Eric L; LEMONS, Philip W; TARDIFF, Barbara E et al.The American heart journal. 2005, Vol 149, Num 3, pp 482-488, issn 0002-8703, 7 p.Article

Essais cliniques : Principes méthodologiques et aspects éthiques de l'évaluation des thérapeutiques = Clinical trialsMONTAGNE, O; MACQUIN-MAVIER, I; LEJONC, J.-L et al.La Revue du praticien (Paris). 1998, Vol 48, Num 6, pp 679-684, issn 0035-2640Article

A phase II trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia : a southeastern cancer study group studyVOGLER, W. R; VELEZ-GARCIA, E; WEINER, R. S et al.Journal of clinical oncology. 1992, Vol 10, Num 7, pp 1103-1111, issn 0732-183XArticle

Antiemetic study design : desirable objectives, stratifications and analyses. DiscussionOLVER, I. N; SMYTH; GRALLA et al.British journal of cancer. 1992, Vol 66, pp S30-S34, issn 0007-0920, SUP19Article

Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819REDMAN, Mary W; CROWLEY, John J; HERBST, Roy S et al.Clinical cancer research (Print). 2012, Vol 18, Num 15, pp 4004-4012, issn 1078-0432, 9 p.Article

Design and analysis of phase III trials with ordered outcome scales: The concept of the sliding dichotomyMURRAY, Gordon D; BARER, David; TAYLOR, Gillian S et al.Journal of neurotrauma. 2005, Vol 22, Num 5, pp 511-517, issn 0897-7151, 7 p.Article